Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan;51(1):14-8.
doi: 10.1002/mus.24470. Epub 2014 Nov 24.

Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis

Martin R Turner  1 , Michael Benatar
Affiliations
Free PMC article
Review

Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis

Martin R Turner et al. Muscle Nerve. 2015 Jan.
Free PMC article

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Muscle Nerve. 2015 Apr;51(4):628. doi: 10.1002/mus.24596. Epub 2015 Feb 6. Muscle Nerve. 2015. PMID: 25656323 Free PMC article. No abstract available.

Abstract

Multiple candidate biomarkers for amyotrophic lateral sclerosis (ALS) have emerged across a range of platforms. Replication of results, however, has been absent in all but a few cases, and the range of control samples has been limited. If progress toward clinical translation is to continue, the specific biomarker needs of ALS, which differ from those of other neurodegenerative disorders, as well as the challenges inherent to longitudinal ALS biomarker cohorts, must be understood. Appropriate application of multimodal approaches, international collaboration, presymptomatic studies, and biomarker integration into future therapeutic trials are among the essential priorities going forward.

Keywords: biomarker; motor neuron disease; neurochemistry; neuroimaging; trial.

PubMed Disclaimer

Comment in

References

    1. Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12:310–322. - PMC - PubMed
    1. Bradley WG. Biological markers in amyotrophic lateral sclerosis: help or hindrance? J Neurol. 1999;246(suppl 3):iii13–15. - PubMed
    1. Poser CM, Johnson M, Bunch LD. Serum amino acid studies in amyotrophic lateral sclerosis I. results of arginine tolerance tests. Arch Neurol. 1965;12:604–609. - PubMed
    1. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8:94–109. - PubMed
    1. Bowser R, Turner MR, Shefner J. Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol. 2011;7:631–638. - PubMed

Publication types

MeSH terms